 | |
| Company type | Public |
|---|---|
| Nasdaq: GBIM | |
| Industry | Biotechnology |
| Founded | 1 January 1995
 |
| Headquarters | , |
Number of employees | 22 (Dec 2014) [1] |
| Website | GlobeImmune.com |
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. [2] As of August 2014 [update], the company had no marketed products. [3][ self-published source] GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene (established in 2009) [2] and the National Cancer Institute for the development of cancer vaccines. [4] [5] Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before. [6]
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010. [2]
As of August 2015 [update], GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. [7] Completed trials have addressed two other candidates, GI-4000 (the company's lead oncology candidate as of 2010) [2] and GI-5005. [7] Despite there being three ongoing trials, in July 2015 the company announced it would eliminate "most of its workforce positions" shortly following the failure of a trial examining GI-4774. [1]
In March 2017, GlobeImmune announced that it has entered into a definitive purchase agreement for the sale of shares of its common stock to NantCell, Inc. [8]
References
- ^ a b "Industry Watch". Genetic Engineering & Biotechnology News. 35 (13): 8–8. July 2015. doi: 10.1089/gen.35.13.04.
- ^ a b c d Staff (19 January 2010). "GlobeImmune Raises $17.5M in Series E Financing". Genetic Engineering & Biotechnology News. Retrieved 2015-08-19.
- ^ "About GlobeImmune" (PDF). GlobeImmune. 22 August 2014. Retrieved 2015-08-19.
- ^ "GlobeImmune and Celgene Corporation Announce Strategic Global" (Press release). Celgene. 15 May 2009 – via Bloomberg.
- ^ Staff (16 April 2009). "GlobeImmune starts cancer drug trial". BizWest. Colorado, United States: BizWest Media.
- ^ Adams, Ben (November 18, 2016). "GlobeImmune draws the curtain as Gilead kills drug deal, CEO role abandoned". FierceBiotech.
- ^ a b "Search of:globeimmune". ClinicalTrials.gov. United States National Institutes of Health.
- ^ "GlobeImmune Announces Majority Stock Sale". www.prnewswire.com (Press release). Retrieved 2020-02-24.
External links
|
| |
| Company type | Public |
|---|---|
| Nasdaq: GBIM | |
| Industry | Biotechnology |
| Founded | 1 January 1995
|
| Headquarters | , |
Number of employees | 22 (Dec 2014) [1] |
| Website | GlobeImmune.com |
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. [2] As of August 2014 [update], the company had no marketed products. [3][ self-published source] GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene (established in 2009) [2] and the National Cancer Institute for the development of cancer vaccines. [4] [5] Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before. [6]
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010. [2]
As of August 2015 [update], GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. [7] Completed trials have addressed two other candidates, GI-4000 (the company's lead oncology candidate as of 2010) [2] and GI-5005. [7] Despite there being three ongoing trials, in July 2015 the company announced it would eliminate "most of its workforce positions" shortly following the failure of a trial examining GI-4774. [1]
In March 2017, GlobeImmune announced that it has entered into a definitive purchase agreement for the sale of shares of its common stock to NantCell, Inc. [8]
References
- ^ a b "Industry Watch". Genetic Engineering & Biotechnology News. 35 (13): 8–8. July 2015. doi: 10.1089/gen.35.13.04.
- ^ a b c d Staff (19 January 2010). "GlobeImmune Raises $17.5M in Series E Financing". Genetic Engineering & Biotechnology News. Retrieved 2015-08-19.
- ^ "About GlobeImmune" (PDF). GlobeImmune. 22 August 2014. Retrieved 2015-08-19.
- ^ "GlobeImmune and Celgene Corporation Announce Strategic Global" (Press release). Celgene. 15 May 2009 – via Bloomberg.
- ^ Staff (16 April 2009). "GlobeImmune starts cancer drug trial". BizWest. Colorado, United States: BizWest Media.
- ^ Adams, Ben (November 18, 2016). "GlobeImmune draws the curtain as Gilead kills drug deal, CEO role abandoned". FierceBiotech.
- ^ a b "Search of:globeimmune". ClinicalTrials.gov. United States National Institutes of Health.
- ^ "GlobeImmune Announces Majority Stock Sale". www.prnewswire.com (Press release). Retrieved 2020-02-24.